China’s Shenzhen Hepalink to issue up to RMB 1.5 billion bonds

By William Gullotti

Buffalo, N.Y., Dec. 13 – Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is seeking shareholder approval for a proposed issuance of up to RMB 1.5 billion corporate bonds, according to an announcement on Monday.

The proposed bonds may be issued in multiple tranches with maturities not exceeding five years and will be guaranteed by Shenzhen Gaoxin Investment and Financing Guarantee Co., Ltd.

Shareholder voting will take place at the extraordinary general meeting scheduled for Jan. 4.

If approved, proceeds from the issuance will be used to repay debts, adjust debt structure and replenish working capital.

The company manufactures and distributes pharmaceutical products, including heparin sodium active pharmaceutical ingredients, heparin sodium and enoxaparin sodium.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.